Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.69
-0.07 (-0.51%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 87.27B INR in the quarter ending December 31, 2025, with 4.40% growth. This brings the company's revenue in the last twelve months to 346.33B, up 11.06% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
346.33B INR
Revenue Growth
+11.06%
P/S Ratio
2.96
Revenue / Employee
12,452,806 INR
Employees
27,811
Market Cap
11.40B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | 153.85B | 11.82B | 8.32% |
| Mar 31, 2018 | 142.03B | 1.22B | 0.87% |
| Mar 31, 2017 | 140.81B | -13.90B | -8.98% |
| Mar 31, 2016 | 154.71B | 6.52B | 4.40% |
| Mar 31, 2015 | 148.19B | 16.02B | 12.12% |
| Mar 31, 2014 | 132.17B | 15.90B | 13.68% |
| Mar 31, 2013 | 116.27B | 19.53B | 20.19% |
| Mar 31, 2012 | 96.74B | 22.04B | 29.51% |
| Mar 31, 2011 | 74.69B | 4.42B | 6.28% |
| Mar 31, 2010 | 70.28B | 836.00M | 1.20% |
| Mar 31, 2009 | 69.44B | 19.44B | 38.87% |
| Mar 31, 2008 | 50.01B | -15.09B | -23.18% |
| Mar 31, 2007 | 65.10B | 40.83B | 168.24% |
| Mar 31, 2006 | 24.27B | 4.75B | 24.32% |
| Mar 31, 2005 | 19.52B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Viatris | 14.30B |
| Elanco Animal Health | 4.72B |
| United Therapeutics | 3.18B |
| Amneal Pharmaceuticals | 3.02B |
| Neurocrine Biosciences | 2.86B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
RDY News
- 2 days ago - Domestic companies launch semaglutide jabs at affordable prices - The Times of India
- 3 days ago - Dr. Reddy's Laboratories launches India's first DCGI-approved semaglutide injection - Business Upturn
- 10 days ago - Dr. Reddy's Laboratories updates on Eftilagimod Alfa trial discontinuation - Business Upturn
- 12 days ago - Dr. Reddy's Laboratories issues 10,275 equity shares under stock options scheme - Business Upturn
- 15 days ago - What is dragging Dr Reddy’s shares 2% down today? Explained - Business Upturn
- 18 days ago - Top stocks to watch today, March 6: TCS, Tata Elxsi, GE Shipping, GRSE, Dr Reddy’s Lab, Mazagon Dock, Wipro, Bharat Forge, Angel One in focus - Business Upturn
- 19 days ago - Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's - Nasdaq
- 25 days ago - Top losers among Nifty 50 stocks in midday trades today, Feb 27: Dr. Reddy’s falls 2.8%, Bharti Airtel down 2.7%, Grasim Industries drops 2.5% - Business Upturn